Myristica fragrans Houtt. methanol extract as a promising treatment for Cryptosporidium parvum infection in experimentally immunosuppressed and immunocompetent mice

Bibliographic Information
Authors: El Shanawany E.E.; Abouelmagd F.; Taha N.M.; Zalat R.S.; Abdelrahman E.H.; Abdel-Rahman E.H.
Journal: Veterinary World
Publisher: Veterinary World
Publication Date: 15 September 2024
Volume / Issue: Volume 17 / Issue 9
Pages: 2062–2071
ISSN: 9728988
DOI: 10.14202/vetworld.2024.2062-2071
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
El Shanawany E.E., Department of Parasitology and Animal Diseases, National Research Centre, Dokki, Giza, Egypt; Abouelmagd F., Department of Medical Parasitology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt; Taha N.M., Department of Parasitology, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Zalat R.S., Department of Parasitology, Theodor Bilharz Research Institute, Egypt; Abdelrahman E.H., Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, Egypt; Abdel-Rahman E.H., Department of Parasitology and Animal Diseases, National Research Centre, Dokki, Giza, Egypt
Abstract
Background and Aim: Cryptosporidiosis is a major waterborne disease affecting ruminants and humans worldwide. It causes diarrhea and neonatal mortality in buffalo calves, and watery diarrhea and mortality in children and immunodeficient patients. This study aimed to investigate the efficacy of Myristica fragrans methanolic extract in treatment of C. parvum infection in comparison with nitazoxanide (NZX) (a Food and Drug Administration-approved drug control) in immunosuppressed and immunocompetent mice. Materials and Methods: One hundred laboratory-bred male Swiss albino mice were equally divided into immunocompetent and immunosuppressed groups. Each group was further divided into five subgroups: (1) non-infected and non-treated control, (2) infected and non-treated control (infected with Cryptosporidium parvum oocysts 3 × 103), (3) NZX-treated (100 mg/kg, 200 μL/mouse), (4) M. fragrans Houtt. methanol extract-treated (500 mg/kg), and (5) combination-treated (NZX + M. fragrans extract). Number of oocysts/g of feces, serum immunoglobulin (Ig) G level, and interferon (IFN)-γ, and interleukin (IL)-4 levels were used to evaluate the therapeutic effect. Results: C. parvum oocyst shedding in stool samples was significantly decreased in all treatment groups, with 79.7%, 81.2 %, and 85.5 % reduction in immunocompetent mice treated with NZX, M. fragrans, and their combination, respectively. In immunosuppressed mice, oocyst shedding was reduced by 77.7%, 80.5 %, and 83.7 % upon NZX, M. fragrans, and their combination treatments, respectively. The serum IgG level was lowest in mice treated with a mixture of M. fragrans and NZX, followed by those treated with NZX, and was highest in mice treated with M. fragrans alone. Regarding cytokine levels, all groups treated with M. fragrans had low levels of IFN-γ and IL4 on day 21 post-infection. Conclusion: Collectively, the treatment of cryptosporidiosis with M. fragrans extract was successful in mice, as demonstrated by the measured parameters. M. fragrans reduced C. parvum oocyst shedding and serum IgG, IFN-γ, and IL-4 levels in immunocompetent and immunosuppressed mice. © 2024 Veterinary World. All rights reserved.
Keywords
Cryptosporidium parvum; gas chromatography-mass spectrometry; immunosuppressed mice and immunocompetent mice; Myristica fragrans Houtt.; treatment; antigen; dexamethasone; gamma interferon; heparin; immunoglobulin G; interleukin 4; methanol; nitazoxanide; plant extract; thiopental; animal experiment; animal model; Article; blood sampling; controlled study; cryptosporidiosis; drug efficacy; enzyme linked immunosorbent assay; feces analysis; immunosuppressive treatment; male; mouse; nonhuman; nutmeg; oocyst; optical density; parasitology; pyrolysis gas chromatography mass spectrometry
Citation Information
Scopus Citations: 7
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
